Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients

The emerging debate between primary tumor location and clinical outcome of bevacizumab treated metastatic colorectal cancer (mCRC) continues. The aim of the present study is to investigate the association between the primary tumor location and clinical outcome of 115 mCRC patients receiving bevacizu...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Xia-Hong, Wen, Can, Xia, Zi-Jin, Sun, Fan, Li, Yao, Wang, Wei, Fang, Zhou, Chen, Qing-Gen, Zhang, Lei, Jiang, Yu-Huang, Wang, Xiao-Zhong, Ying, Hou-Qun, Zong, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702298/
https://www.ncbi.nlm.nih.gov/pubmed/31475100
http://dx.doi.org/10.3389/fonc.2019.00723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702298/
https://www.ncbi.nlm.nih.gov/pubmed/31475100
http://dx.doi.org/10.3389/fonc.2019.00723

Ejemplares similares